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ABSTRACT
Background: Balkan endemic nephropathy (BEN)
hemodialysis patients require a higher dose of
recombinant human erythropoietin for maintaining target
hemoglobin level than patients with other kidney diseases.
Objectives: Comparison of the pharmacokinetics of beta-
erythropoietin given subcutaneously to hemodialysis
patients with BEN or other kidney diseases (non-BEN).
Methods: Recombinant human erythropoietin (75U/kg)
was administered subcutaneously to 10 BEN and 14 non-
BEN hemodialysis patients. The predose plasma level of
erythropoietin (Epo) was subtracted from all postdose
levels. The relevant pharmacokinetic parameters were
calculated after noncompartmental pharmacokinetic
analysis using Kinetica software (Thermo Scientific,
ver.5.0). Results: Although basal plasma Epo
concentration was similar in BEN (20.1±10.3U/L) and non-
BEN (15.1±8.1U/L; p=.1964) patients, there were significant
differences between the groups for elimination rate
constant (0.016±0.006 vs 0.026±0.011 hr-1; p=.020) and
elimination half-life (50.24±19.12 vs 33.79±18.91 hr,
p=.048). These differences remained significant after
adjustment for patient characteristics (age, sex,
hemodialysis duration, ferritin, PTH and ACEI use). No
significant differences between groups were found in
maximal Epo concentration, time to maximum Epo
concentration, area under the curve from time of dosing
extrapolated to infinity, clearance, mean residence time of
Epo between groups both before and after adjustment.
Conclusion: Pharmacokinetic analysis of beta-
erythropoietin detected a significantly longer elimination
half-life in BEN than in non BEN patients. This finding
needs to be confirmed in a well-controlled study with a
larger sample size.
Keywords: Balkan endemic nephropathy. Human 
recombinant erythropoietin. Pharmacokinetics.
La farmacocinética de la eritropoyetina recombinante
humana en pacientes con nefropatía endémica de los
Balcanes
RESUMEN
Antecedentes: Los pacientes con nefropatía endémica
de los Balcanes (NEB) en hemodiálisis necesitan una do-
sis más elevada de eritropoyetina recombinante huma-
na que los pacientes con otras enfermedades renales
para poder mantener el nivel de hemoglobina deseado.
Objetivos: Comparar la farmacocinética de la eritropo-
yetina beta administrada subcutáneamente a pacientes
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en hemodiálisis con NEB u otras enfermedades renales.
Métodos: A 10 pacientes hemodializados con NEB y 14
pacientes hemodializados con otras enfermedades re-
nales se les administró subcutáneamente eritropoyeti-
na (EPO) recombinante humana (75 U/kg). El nivel de
EPO en plasma previo a la dosis se sustrajo de todos los
niveles que se obtuvieron tras administrarla. Los pará-
metros farmacocinéticos relevantes se calcularon tras el
análisis farmacocinético no compartimental con ayuda
de la aplicación Kinetica (Thermo Scientific, versión
5.0). Resultados: Aunque la concentración basal de
EPO en el plasma era similar en pacientes con NEB (20,1
± 10,3 U/l) y en pacientes con otras enfermedades re-
nales (15,1 ± 8,1 U/l; p = 0,1964), se apreciaron dife-
rencias significativas entre los grupos con respecto a la
constante de eliminación (0,016 ± 0,006 vs. 0,026 ±
0,011 h-1; p = 0,020) y a la semivida de eliminación
(50,24 ± 19,12 vs. 33,79 ± 18,91 h, p = 0,048). Estas
diferencias resultaron igualmente significativas tras
ajustar los valores en función de las características de
los pacientes (edad, sexo, duración de la hemodiálisis,
ferritina, hormona paratiroidea y uso de inhibidores de
la enzima de conversión de la angiotensina). No obs-
tante, no se observaron diferencias significativas entre
los grupos en los siguientes parámetros ni antes ni des-
pués de efectuar los ajustes pertinentes: concentración
máxima de EPO, tiempo en alcanzar la concentración
máxima de EPO, área bajo la curva extrapolada al infi-
nito a partir de la administración de la dosis, aclara-
miento y tiempo medio de permanencia de la EPO.
Conclusión: El análisis farmacocinético de la eritropo-
yetina beta reveló que la semivida de eliminación era
significativamente más larga en los pacientes con NEB,
hallazgo que debe ser confirmado en un estudio bien
controlado con una muestra más grande.
Palabras clave: Nefropatía endémica de los Balcanes.
Eritropoyetina recombinante humana. Farmacocinética.
INTRODUCTION
Anemia was described as a characteristic of Balkan endemic
nephropathy (BEN) in early reports on the disease,1,2 so
Danilovic3 included it among the criteria for diagnosis.
However, several authors reported no significant differences
between anemia in BEN and other kidney diseases.4-6 Thus,
although anemia in BEN patients deteriorates with
progressive renal failure similarly as in patients with other
kidney diseases, it was more severe in BEN patients on
hemodialysis than in those with other kidney diseases.6,7
We recently showed that BEN hemodialysis patients required
a higher dose of recombinant human erythropoietin for
maintaining the target hemoglobin level than patients with
other kidney diseases.8 Several factors may contribute to the
weaker hematopoietic response to erythropoietin-stimulating
agents (ESA). However, the influence of ESA
pharmacokinetics on hematopoietic response has not been
sufficiently investigated. Pharmacokinetics studies were
mostly devoted to the pharmacokinetics of diverse ESA
administered by different routes,9-13 as well as to the
pharmacokinetics of ESA in various groups of chronic kidney
disease patients and healthy persons.14-16
The aim of this study was to compare the pharmacokinetics
of beta-erythropoietin (beta-Epo) given subcutaneously to
BEN patients and patients with other kidney diseases (non-
BEN) and to evaluate the factors influencing beta-Epo
kinetics.
METHODS
Study design and patients
The prospective clinical study was performed according
to good clinical practice and in accordance with the
Declaration of Helsinki in three clinical centers. The
Ethics Committee of the Clinical Center of Serbia
evaluated and approved the study and the participants
gave informed consent.
A total of 24 subjects was selected from the population of
256 hemodialysis patients according to the following
inclusion criteria: stable individuals on regular
hemodialysis, treated with beta-Epo for at least 1 year.
Exclusion criteria were: treatment with ESA other than
beta-Epo; anemia from causes other than chronic kidney
disease - blood loss, malignancy, acute infection,
hemolysis, major surgery; liver disease (twice or half
normal values for transaminases); blood transfusion
within one month before enrolment; severe psychiatric
dysfunction or other limitations preventing the patient to
give consent. Among the remaining 96 patients (40 BEN
and 56 others) who met inclusion criteria, 10 with BEN
and 14 with other kidney diseases were selected using
systematic sampling i.e every 10th patient from each
group was assigned for study. The group with other
kidney diseases consisted of 8 patients with
glomerulonephritis, 3 with hypertensive nephropathy, 2
with reflux nephropathy and 1 with polycystic kidney
disease.
All patients were treated thrice weekly for 4-5 h by
standard bicarbonate hemodialysis using polysulphone
membrane dialyzers. Data on patients’ weight, blood
pressure, use of angiotensin converter enzyme inhibitors
(ACEI) and angiotensin II receptor antagonists (ARA II),
hemoglobin, rHuEpo dose and iron treatment were
obtained from medical records. Serum levels of iron,
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ferritin, transferrin saturation, C-reactive protein (CRP),
albumin, urea, creatinine, calcium, phosphate and
parathyroid hormone (PTH) were determined in each
patient at the time of study.
Beta-erythropoietin administration and blood
sampling
All patients had been treated with beta-Epo (Epoetin-beta,
Recormon®, Roche) for more than 6 months and during the
study received beta-Epo twice weekly, at the end of the first
and third hemodialysis in the week. The dose of beta-Epo
was adjusted to attain the hemoglobin target range defined
by European best practice guidelines for the management of
anemia in patients with chronic renal failure17. In addition,
iron status was assessed and supplementary iron given
according to the same guidelines.
The last beta-Epo dose prior to pharmacokinetics blood
sampling was omitted in all patients but recontinued at the
first hemodialysis session after the study with the dose used
before. For pharmacokinetic assessment 75U/kg of beta-Epo
was administered subcutaneously at the end of the first
hemodialysis in the week. Venous blood was collected into
heparinized tubes before and at 2, 6, 8, 12, 24, 48, and 72
(only in five patients) h after beta-Epo administration. Blood
samples were centrifuged for 10 min and plasma stored
frozen until analysis. Erythropoietin (Epo) concentration was
determined in all samples on the same day by
chemiluminescent immunoassay for erythropoietin on an
Immulite 2000 analyzer (Siemens Healthcare Diagnostics).
Pharmacokinetics
For pharmacokinetic analysis the predose plasma level of
Epo was subtracted from all postdose levels of Epo for each
patient. Noncompartmental pharmacokinetic analysis using
Kinetica software (Thermo Scientific, ver. 5.0) was
performed in order to calculate following pharmacokinetic
parameters: terminal elimination rate constant (β), half-life
of elimination (t
1/2
), maximum concentration (C
max
), time of
reaching C
max
(t
max
), area under the curve from time of dosing
extrapolated to infinity (AUC), apparent volume of
distribution (Vd/F), apparent clearance (CL/F), mean
residence time (MRT).
Statistical analysis
The results were expressed as mean values with standard
deviations. The significance of differences between mean
values for groups was calculated using the Mann-Whitney
U test and Student’s t-test. One-way ANOVA was used to
compare pharmacodynamics parameters between the
groups (BEN and non-BEN). Analysis of covariance
(ANCOVA) was used to adjust these differences for patient
characteristics that differed between groups: age, sex,
hemodialysis duration, ferritin, PTH as well as ACEI use.
All analyses were performed using the SPSS (ver. 20)
program.
RESULTS
The study involved 24 hemodialysis patients, 10 patients
with BEN and 14 with other kidney diseases, selected from
96 patients (40 BEN and 56 others) who met the inclusion
criteria. Their main characteristics are presented in Table 1.
Patients with BEN were significantly older and had spent
less time on hemodialysis than non-BEN patients. No
between group differences were found for gender, mean
weight, Kt/V and the proportion of subjects using ACEI.
None of the participants used ARA II.
Results of laboratory analyses in the examined individuals
are given in Table 2. Mean hemoglobin level for the BEN
group was 112±5.5g/L and for the non-BEN group
109±4.4g/L, and mean beta-Epo doses were 87±16.5 and
66.5±28.3U/kg/week (p=.051), respectively. Iron reserves
were significantly higher in the BEN than in the non-BEN
group. Predialysis serum creatinine and PTH
concentrations were significantly lower, and serum
calcium concentration was significantly higher in the BEN
than in the non-BEN group. Basal plasma Epo
concentration in BEN patients ranged between 7.2 and
40.1U/L and in non-BEN patients between 6.7 and
31.2U/L, but the difference between the two groups for
mean concentration was not statistically significant
(20.1±10.3U/L; vs. 15.1±8.1U/L; p=.1964).
The individual profiles of Epo concentration after
subcutaneous administration of 75U/kg of beta-Epo are
presented in Figures 1 and 2. After beta-Epo
administration plasma Epo slowly increased and C
max
was
achieved after 10.6±2.2 h in BEN patients, and after
14.6±6.16 h in non-BEN patients (p=.697). The presented
profiles show greater inter-individual variability in Epo
concentration but a faster decrease of Epo level during the
elimination phase in non-BEN than in BEN patients.
The pharmacokinetic parameters of Epo are presented in
Table 3. BEN patients differed markedly from non-BEN
patients only in β (0.016±0.006 vs. 0.026±0.011L/h;
p=.021) and t
1/2
(50.24±19.12 vs. 33.79±18.91h, p= 0.048).
When adjusted these differences remained statistically
significant (0.017±0.011 vs. 0.026±0.009; p=.038 and
57.10±24.54 vs. 33.32±9.12; p=.032 respectively). Also,
the difference in other pharmacokinetic parameters
presented in table 3 remained insignificant after
adjustment.
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DISCUSSION
In the present study beta-Epo pharmacokinetics was
examined in BEN and non-BEN patients. After subcutaneous
administration of 75U/kg of beta-Epo, plasma Epo
concentration profiles showed smaller inter-individual
variability in BEN than in non-BEN patients. The value of t
1/2
was significantly greater in BEN than in non-BEN patients,
but the difference in C
max
and t
max
was not detected under this
study design.
A number of pharmacokinetic studies of ESA have been
published, but comparison between them is difficult due to
numerous methodological differences. Recent studies were
largely devoted to the pharmacokinetics of new ESAs10,12,14
and were usually carried out in healthy persons. The present
study was initiated from earlier data involving 146 BEN and
94 non-BEN patients, which showed that significantly higher
beta-Epo doses for reaching and maintaining target
hemoglobin level were necessary in BEN than in non-BEN
patients.8 In the present study the difference in the mean
beta-Epo dose between the two groups examined did not
reach statistical significance, probably due to the small
number of patients involved. A number of factors may
contribute to insufficient hematopoietic response to ESAs:
iron deficiency most often caused by blood loss, secondary
hyperparathyroidism, hemolysis, malignancy, malnutrition,
inadequate dialysis, older age, inflammation.18,19 Most of
these factors were exclusion criteria for this as well as for
our previous study. In addition, none of the mentioned
factors for Epo hyporesponsiveness were significantly more
pronounced in BEN than in non-BEN patients, except for
Table 1. Main characteristics of the patients
BEN Non-BEN
10 patients 14 patients
Gender: male, number 6 7
Age, years 70.9 ± 7.1 49.6±14.4a
Weight, kg 70.4±12.3 66.4±13.1
Dialysis duration, months 43.9 ± 34.7 106.6±59.4a
Virus hepatitis positive, number 0
Kt/V 1.45±0.23 1.61±0.25
ACEI use, yes/no 6/4 5/9
Iron supplementation, yes/no 6/4 11/3
Beta-Epo dose, U/kg/week 87.0±16.48 66.5±28.28
ACEI: angiotensin converter enzyme inhibitors.
a p<.05 for statistical significance between groups.
Table 2. Results of laboratory analyses in examined patients
BEN patients Non-BEN patients
Hemoglobin, g/L 112.2±5.50 108.9±4.37
Iron, µmol/L 14.3±7.0 13.3±2.9
Transferrin saturation, % 34.5±21.7 34.31±19.7
Ferritin, µg/L 1161.43±882.31 572.42±347.16a
CRP, mg/L 8.66±6.64 6.83±3.17
Albumin, g/L 38.58±2.36 40.46±3.22
Serum urea, mmol/L 22.34±4.9 21.42±3.5
Serum creatinine, µmol/L 763.2±129.2 956.85±190.3a
Serum calcium, mmol/L 2.49+0.29 2.22+0.14a
Serum phosphate, mmol/L 1.43+0.37 1.63+0.49
PTH, pg/ml 94.6±87.4 401.5±390.9a
Epo,  U/L 20.1±10.3IU/L 15.1±8.1IU/L
CRP: C reactive protein; Epo: baseline erythropoietin plasma level; PTH: parathyroid hormone. 
a p<.05 for statistical significance between groups.  
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older age. Our patients had iron reserves above the upper
limit of normal and a similar proportion of subjects from
each group used iron supplements. Elevated CRP20,21 and
PTH21 were found to be associated with delayed or
diminished response to ESA treatment. Our groups had
similar CRP levels but PTH level was significantly lower in
BEN patients than in the others. ACEI and ARA II can
increase the need for ESA18,22 but no significant difference
was found between BEN and non-BEN patients in the
relative number using ACEI (none of them used ARA II).
The question arose whether the difference in beta-Epo dose
could be caused by different pharmacokinetics of Epo in
BEN and non-BEN patients.
After subcutaneous administration of beta-Epo the mean C
max
of Epo in the two groups receiving the same dose did not
differ significantly, but inter-individual differences in this
concentration were higher in non-BEN (coefficient of
variation, CV=48.4%) than in BEN patients (CV=22.4%).
Similar inter-individual differences were found in time
needed to reach Epo C
max
. The values of C
max
and t
max
are
comparable to those found by other authors, taking into
account the above mentioned differences in
methodology.11,16,23,24 Higher inter-individual variability 
in non-BEN compared to BEN patients might be due to
differences in group composition: the BEN group was more
homogenous, consisting of patients with a single disease,
while the non-BEN group included patients with diverse
kidney diseases.
On the other hand, elimination of Epo was slower in BEN
than in non-BEN patients. The value of t
1/2
obtained in non-
BEN patients was comparable to that found elsewhere for
hemodialysis patients11 and healthy individuals.25 This
indicates that BEN patients were characterized by slower
Epo elimination, and therefore with prolonged MRT as well.
MRT above 60 hr had 7/10 BEN patients, but 4/14 non-BEN.
Vd as primary pharmacokinetic parameter, for conventional
drugs, affects the value of t
1/2
in a proportional manner and not
vice versa. Our results suggest that BEN patients have tendency
of higher Vd values, and significantly higher t
1/2
(Table 3).
However, for protein and peptide drugs, dependency on active
tissue uptake, binding to intra- and extravascular proteins can
substantially increase the value of Vd. Therefore, not only the
distribution by itself, but also the process of elimination and
interaction directly with the Epo receptor on the red blood cell
surface play an important role in increasing the values of Vd for
Epo in comparison to its physiological distribution limited to
extravascular space in the body.
Despite long clinical experience with ESAs, the mechanisms
involved in their elimination have not been fully elucidated.
It seems most likely that both native Epo and recombinant
drugs are degraded following receptor-mediated uptake,
mainly in the bone marrow.26-29 It might be speculated that
slower elimination and greater Vd/F of Epo in BEN patients
originated either from lower affinity and slower binding of
Epo to its receptors or reduced internalization and/or
degradation rate. In addition, recently described mechanisms
independent of the Epo receptor elimination pathway,29 may
also contribute to slower Epo elimination in BEN patients.
The main limitation of our study was the small number of
patients in each group, and they were not matched in age.
BEN is a slow progressive chronic kidney disease and
patients who progress to end-stage renal disease usually start
hemodialysis in the seventh decade of life.30 Previous
studies of Epo pharmacokinetics identified age and body
weight as covariates influencing absorption and elimination
of Epo.31-33 In a study of beta-Epo pharmacokinetics in
Figure 2. Plasma erythropoietin concentration profiles in
non-BEN patients after subcutaneous administration of
75U/kg of beta-erythropoietin.
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Figure 1. Plasma erythropoietin concentration profiles in
BEN patients after subcutaneous administration of 75
U/kg of beta-erythropoietin.
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healthy adult males Hayashi et al.31 detected a significant
negative correlation between the elimination rate constant
and age and creatinine. As the main organs involved in Epo
elimination are the kidneys and bone marrow and both
kidney function and bone marrow cellularity decrease with
age, the authors suggested that age and creatinine influence
Epo elimination. Although an impact of age on Epo
elimination in our patients cannot be fully excluded, neither
age nor other covariates that differed between the groups
was found affect Epo elimination in the ANCOVA model.
On the other hand, residual renal function was maintained
longer in BEN patients than in those with other kidney
Table 3. Individual and mean (± SD) values of pharmacokinetic parameters of rHuEpo after subcutaneous administration
of 75 U/kg to examined patients
Group - patient β, t
1/2
Cmax, IU/L AUC, hr*IU/L Vd/F, L/kg CL/F, MRT,
hr-1 hr L/hr/kg hr
BEN-1 0.022 31.48 34.00 2225.41 107.14 2.36 49.61
BEN-2 0.008 86.64 67.30 8035.46 73.50 0.59 123.91
BEN-3 0.010 70.46 71.10 7160.70 88.38 0.87 102.10
BEN-4 0.026 26.59 69.30 3340.09 69.78 1.82 42.20
BEN-5 0.012 59.83 71.30 6690.02 87.09 1.01 87.79
BEN-6 0.024 28.64 51.20 3068.93 72.72 1.76 46.23
BEN-7 0.012 55.81 45.00 4442.88 66.60 0.83 84.67
BEN-8 0.013 52.05 77.20 4926.45 79.45 1.06 74.89
BEN-9 0.015 47.43 64.60 5416.75 53.54 0.78 73.04
BEN-10 0.016 43.47 59.00 3604.71 91.34 1.46 63.19
NonBEN-1 0.025 27.83 99.40 4880.28 30.23 0.75 41.45
NonBEN-2 0.019 35.71 64.90 3863.33 71.01 1.38 54.62
NonBEN-3 0.015 46.61 32.80 2605.31 112.27 1.67 69.42
NonBEN-4 0.033 21.97 172.90 8685.79 21.89 0.69 39.83
NonBEN-5 0.008 80.01 57.60 7819.73 95.69 0.77 126.74
NonBEN-6 0.032 21.53 115.90 4906.05 27.35 0.88 34.66
NonBEN-7 0.025 27.93 45.20 2435.15 75.08 1.86 42.51
NonBEN-8 0.031 22.23 78.30 3163.75 55.50 1.73 36.77
NonBEN-9 0.048 14.57 92.10 3229.53 33.19 1.58 32.64
NonBEN-10 0.014 47.99 99.90 7318.53 50.02 0.72 75.26
NonBEN-11 0.040 17.52 27.80 1199.57 58.48 2.31 27.06
NonBEN-12 0.034 20.21 79.50 2830.39 40.57 1.39 30.89
NonBEN-13 0.026 27.09 68.70 3603.71 50.84 1.30 41.97
NonBEN-14 0.011 61.86 55.00 5035.07 105.69 1.18 90.79
BEN
mean ± SD 0.016±0.006 50.24±19.12 61.00±13.65 4891.1±1921.8 78.95±15.11 1.25±0.57 74.76 ±25.98
NON-BEN
mean ± SD 0.026±0.011 33.79±18.91 77.86±37.65 4398.3±2202.8 59.13±29.27 1.30±0.50 53.18 ±28.21
ANOVA F 6.21 4.37 1.81 0.32 3.82 0.05 3.64
P 0.021 0.048 0.192 0.575 0.063 0.833 0.070
ANCOVA F 4.99 5.23 2.92 3.86 2.07 0.88 2.08
P 0.038 0.032 0.107 0.064 0.176 0.309 0.168
β: terminal elimination rate constant; AUC: area under the curve from time of dosing extrapolated to infinity; CL/F: apparent
clearance; Cmax: maximum concentration; MRT: mean residence time; t
1/2
: half-life of elimination; tmax: time of reaching Cmax;
Vd/F: apparent volume of distribution.
ANCOVA included age, sex, hemodialysis duration, ferritin, PTH and ACEI use as covariates.
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diseases34 and our BEN patients were shorter on
hemodialysis treatment than non-BEN patients. Therefore,
renal clearance of Epo could be higher in BEN than in non-
BEN patients. As previous studies showed that the kidneys
contribute to Epo elimination in a very minor fashion35 and
residual kidney function in patients more than three years on
dialysis is most often negligible, it is not expected that renal
elimination of Epo could be of any influence.
CONCLUSION
Pharmacokinetic analysis of beta-erythropoietin found a
significantly longer t
1/2
in BEN than in non-BEN patients
indicating that treatment with ESA could have different
effects in different diseases. These findings need to be
confirmed in a well-controlled study with a larger sample size
in order to establish population pharmacokinetics of beta-Epo
in BEN patients, to evaluate the effects of physiopathological
factors on the disposition kinetics of beta-Epo and to find
potential predictive factors for dosage individualization.
Acknowledgments
This work was conducted as a part of projects No 175089 and 175023
funded by the Ministry of Science, Education and Technological
Development, Belgrade, Republic of Serbia.
Conflicts of interest
The authors declare that they have no conflicts of interest
related to the contents of this article.
REFERENCES
1. Danilovic V, Djurisic M, Mokranjac M, Stojimirovic B, Zivojinovic J,
Stojakovic P. Néphrites chroniques provoquées par l'intoxication au
plomb par voie digestive (farine). Presse Méd 1957;65:2039-40.
2. Gaon J. Endemic nephropathy in Bosnia. In: The Balkan Nephro-
pathy. Eds. G.E.W. Wolstenholme & J. Knight. Ciba Foundation
Study Group No. 30. London: Churchill; 1967. p. 51-71.
3. Danilovic V. Endemic nephropathy in Yugoslavia. In: Endemic (Bal-
kan) Nephropathy, Proc. 4th Symp., Nis 1979. Eds. S. Strahinjic & V.
Stefanovic. Nis: Inst. Nephr. Haemod; 1981. p. 1-5.
4. Bruckner I, Lazarescu R, Titeica M, Ghirghiescu B, Stroescu F. Der
Mechanismus der Anaemie bie der endemische Nephropathie. In:
Int. Symp. on Endemic Nephropathy, Sofia 1963. Sofia: Bulg. Acad.
Sc. Press; 1965. p. 48-51.
5. Trnacevic’ S, Halilbasic’ A, Ferluga D, Plavljanic’ D, Vizjak A, Durakovic’ H,
et al. Renal function, protein excretion and pathology of Balkan ende-
mic nephropathy. I. Renal function. Kidney Int Suppl 1991;34:S49-S51.
6. Pavlovic-Kentera V, Djukanovic Lj., Clemons GK, Trbojevic S, Dimko-
vic N, Slavkovic A. Anaemia in Balkan endemic nephropathy. Kidney
Int Suppl 1991;34:S46-S48. 
7. Pavlovic-Kentera V, Clemons GK, Trbojevic S, Dimkovic N, Djukano-
vic Lj. Erythropoietin and anemia in  the  progression of Balkan en-
demic nephropathy and other renal diseases. Nephron
1990;54:139-43.
8. Lukic’ Lj, Mitrovic’ Dj, Kovac evic’ S, Stanis ic’ M, Pelemis S, Tes ic’ J, et
al. Higher dose of erythropoietin for anemia correction in Balkan en-
demic nephropathy patients. Srp arh cel lek 2012;140:456-61.
9. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et
al. Pharmacokinetics of novel erythropoiesis stimulating protein
compared with epoetin alfa in dialysis patients. J Am Soc Nephrol
1999;10:2392-5.
10. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P,
et al. Pharmacokinetics and pharmacodynamics of intravenous and
subcutaneous continuous erythropoietin receptor activator
(C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc
Nephrol 2006;1:1211-5.
11. Pérez-Oliva JF, Casanova-González M, García-García I, Porrero-Mar-
tín PJ, Valenzuela-Silva CM, Hernández-Montero T, et al.; Bioequi-
valence Study of Erythropoietin Group. Comparison of two recom-
binant erythropoietin formulations in patients with anemia due to
end-stage renal disease on hemodialysis: a parallel, randomized,
double blind study. BMC Nephrol 2005;6:5
12. Togawa A, Tanaka T, Nagashima S, Keta H, Kobayashi Y, Nishikawa
Y, et al. A comparison of the bioequivalence of two formulations of
epoetin alfa after subcutaneous injection. Br J Clin Pharmacol
2004;58:269-76.
13. Jensen JD, Jensen LW, Madsen JK. The pharmacokinetics of recom-
binant human erythropoietin after subcutaneous injection at diffe-
rent sites. Eur J Clin Pharmacol 1994;46:333-7.
14. Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ. Population
pharmacokinetics and pharmacodynamics of peptidic erythropoiesis
receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol
2008;48:43-52.
15. Chanu P, Gieschke R, Charoin J-E, Pannier A, Reigner B. Population
pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-
naïve and ESA-treated chronic kidney disease patients with renal
anemia. J Clin Pharmacol 2010:50;507-20.
16. Kawakami K, Takama H, Nakashima D, Tanaka H, Uchida E, Akiza-
wa T. Population pharmacokinetics of darbepoetin alfa in peritoneal
dialysis and non-dialysis patients with chronic kidney disease after
single subcutaneous administration. Eur J Clin Pharmacol
2009;65:169-78.
17. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et
al. European best practice guidelines working group: revised Euro-
pean best practice guidelines for the management of anaemia in
patients with chronic renal failure. Nephrol Dial Transplant 2004;19
Suppl 2:ii1-ii47.
18. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and
predictors of epoetin hyporesponsiveness in chronic kidney disease
patients. Nephrol Dial Transplant 2007;22:794-800.
19. de Francisco ALM, Stenvinkel P, Vaulont S. Inflammation and its im-
pact on anaemia in chronic kidney disease: from haemoglobin va-
riability to hyporesponsiveness. NDT Plus 2009;2 Suppl 1:i18-i26.
11800_03  16/7/13  09:41  Página 484
artículo especial
485
Visnja Lezaic’ et al. EPO Pharmacokinetics in Balkan Nephropathy
Nefrologia 2013;33(4):478-85
20. Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M,  Ha-
kim RH. Impact of elevated C-reactive protein levels on erythropoie-
sis stimulating agent (ESA) dose and responsiveness in hemodialysis
patients. Nephrol Dial Transplant 2009;24:919-25.
21. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et
al.; Trial to Reduce Cardiovascular Events with Aranesp Therapy
(TREAT) Investigators. Erythropoietic response and outcomes in kid-
ney disease and type 2 diabetes. N Engl J Med 2010;363:1146-55.
22. Guerrero-Riscos MÁ, Montes-Delgado R, Seda-Guzmán M, Praena-
Fernández JM. Erythropoietin resistance and survival in non-dialysis
patients with stage 4-5 chronic kidney disease and heart disease.
Nefrologia 2012;32(3):343-52.
23. Jensen JD, Madsen JK, Jensen LW, Pedersen EB. Reduced produc-
tion, absorption, and elimination of erythropoietin in uremia com-
pared with healthy volunteers. J Am Soc Nephrol 1994;5:177-85.
24. McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M.
Pharmacokinetic and pharmacodynamic profiles of extended do-
sing of epoetin alfa in anemic patients who have chronic kidney
disease and are not on dialysis. Clin J Am Soc Nephrol
2008;3:1006-14.
25. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of
recombinant human erythropoietin after intravenous and subcu-
taneous administration to healthy subjects. Br J Clin Pharmacol
1990;29:709-13.
26. Jelkmann W. The enigma of the metabolic fate of circulating eryth-
ropoietin (Epo) in view of the pharmacokinetics of the recombi-
nant drugs rhEpo and NESP. Eur J Haematol 2002;69:265-74.
27. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common me-
chanism of action. Exp Hematol 2008;36:1573-84.
28. Gross AW, Lodish HF. Cellular trafficking and degradation of eryth-
ropoietin and novel erythropoiesis stimulating protein (NESP). J Biol
Chem 2006;281:2024-32.
29. Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G, et al. In-
vestigation of the effects of altered receptor binding activity on the
clearance of erythropoiesis-stimulating proteins: Nonerythropoietin
receptor-mediated pathways may play a major role. J Pharm Sci
2009;98:2198-211.
30. Bukvic D, Jankovic S, Maric I, Stosovic M, Arsenovic A, Djukanovic
L. Today Balkan endemic nephropathy is a disease of the elderly
with a good prognosis. Clin Nephrol 2009;72:105-13. 
31. Hayashi N, Kinoshita H, Yukawa E, Higuchi S. Pharmacokinetic
analysis of subcutaneous erythropoietin administration with nonli-
near mixed effect model including endogenous production. Br J
Clin Pharmacol 1998;46:11-9.
32. Chakraborty A, Natarajan J, Guilfoyle M, Morgan N, Vercammen E,
Cheung W. Population pharmacokinetics of erythropoietin in criti-
cally ill subjects. J Clin Pharmacol 2005;45:193-202.
33. Agoram B, Sutjandra L, Sullivan JT. Population pharmacokinetics of
darbepoetin alfa in healthy subjects. Br J Clin Pharmacol
2007;63:41-52.
34. Djukanovic Lj, Radovanovic Z.  Balkan nephropathy. In: De Broe ME,
Porter GA, (eds). Clinical Nephrotoxins. Renal Injury from Drugs and
Chemicals, third edition. New York: Springer; 2008. p. 843-58.
35. Yoon WH, Park SJ, Kim IC, Lee MG. Pharmacokinetics of recombi-
nant human in rabbits and 3/4 nephrectomized rats. Res Commun
Mol Pathol Pharmacol 1997;96:227-40.
Enviado a Revisar: 1 Nov. 2012 | Aceptado el: 2 Abr. 2013
11800_03  16/7/13  09:41  Página 485
View publication stats
